PFG Investments LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 67.6% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,999 shares of the biopharmaceutical company's stock after selling 25,026 shares during the quarter. PFG Investments LLC's holdings in Gilead Sciences were worth $1,345,000 as of its most recent filing with the SEC.
Other institutional investors have also modified their holdings of the company. Jamison Private Wealth Management Inc. lifted its position in Gilead Sciences by 2.4% in the 1st quarter. Jamison Private Wealth Management Inc. now owns 28,616 shares of the biopharmaceutical company's stock valued at $3,206,000 after purchasing an additional 659 shares during the last quarter. Covea Finance bought a new stake in Gilead Sciences in the 1st quarter valued at about $3,418,000. Advisor Resource Council bought a new stake in Gilead Sciences in the 1st quarter valued at about $995,000. CPA Asset Management LLC bought a new stake in Gilead Sciences in the 1st quarter valued at about $229,000. Finally, Abundance Wealth Counselors lifted its position in Gilead Sciences by 1.6% in the 1st quarter. Abundance Wealth Counselors now owns 28,155 shares of the biopharmaceutical company's stock valued at $3,142,000 after purchasing an additional 443 shares during the last quarter. Institutional investors own 83.67% of the company's stock.
Analyst Ratings Changes
Several brokerages recently weighed in on GILD. Morgan Stanley lifted their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Wells Fargo & Company lifted their price objective on shares of Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. Bank of America lifted their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research note on Wednesday, March 5th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Nine analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $110.55.
Get Our Latest Stock Analysis on Gilead Sciences
Gilead Sciences Price Performance
NASDAQ:GILD opened at $108.50 on Friday. The business's 50-day moving average price is $106.16 and its 200 day moving average price is $102.81. The firm has a market cap of $134.97 billion, a P/E ratio of 22.84, a PEG ratio of 0.70 and a beta of 0.29. Gilead Sciences, Inc. has a 52-week low of $66.01 and a 52-week high of $119.96. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. Gilead Sciences's revenue was down .3% on a year-over-year basis. During the same quarter last year, the business posted ($1.32) EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.
Gilead Sciences Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, June 27th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.91%. Gilead Sciences's dividend payout ratio (DPR) is presently 66.53%.
Insider Buying and Selling at Gilead Sciences
In other news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Thursday, May 15th. The stock was sold at an average price of $99.82, for a total transaction of $249,550.00. Following the completion of the sale, the chief financial officer now directly owns 165,674 shares in the company, valued at $16,537,578.68. The trade was a 1.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction dated Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the sale, the chief executive officer now owns 620,268 shares of the company's stock, valued at approximately $68,489,992.56. This represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 48,500 shares of company stock valued at $5,236,245 in the last 90 days. 0.27% of the stock is currently owned by corporate insiders.
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
